ATE374838T1 - Nukleotidsequenzvariation im gen ns5a als marker - Google Patents

Nukleotidsequenzvariation im gen ns5a als marker

Info

Publication number
ATE374838T1
ATE374838T1 AT05008605T AT05008605T ATE374838T1 AT E374838 T1 ATE374838 T1 AT E374838T1 AT 05008605 T AT05008605 T AT 05008605T AT 05008605 T AT05008605 T AT 05008605T AT E374838 T1 ATE374838 T1 AT E374838T1
Authority
AT
Austria
Prior art keywords
marker
nucleotide sequence
sequence variation
ns5a gene
ns5a
Prior art date
Application number
AT05008605T
Other languages
English (en)
Inventor
Andrew Michael Ackrill
Karina Anna Orle
Morris Paterson
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE374838T1 publication Critical patent/ATE374838T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT05008605T 2004-04-29 2005-04-20 Nukleotidsequenzvariation im gen ns5a als marker ATE374838T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56627404P 2004-04-29 2004-04-29

Publications (1)

Publication Number Publication Date
ATE374838T1 true ATE374838T1 (de) 2007-10-15

Family

ID=34935435

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05008605T ATE374838T1 (de) 2004-04-29 2005-04-20 Nukleotidsequenzvariation im gen ns5a als marker

Country Status (8)

Country Link
US (2) US7504217B2 (de)
EP (1) EP1591539B1 (de)
JP (1) JP4097662B2 (de)
CN (1) CN100422346C (de)
AT (1) ATE374838T1 (de)
CA (1) CA2503336A1 (de)
DE (1) DE602005002673T2 (de)
ES (1) ES2294589T3 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010025380A2 (en) * 2008-08-28 2010-03-04 Vertex Pharmaceuticals Incorporated Analysis of hcv genotypes
CN102448458B (zh) * 2009-03-18 2015-07-22 小利兰·斯坦福大学理事会 治疗黄病毒科病毒感染的方法和组合物
US20100316608A1 (en) * 2009-06-15 2010-12-16 Vijayaprakash Suppiah Method of Determining A Response To Treatment With Immunomodulatory Composition
EP2558592B1 (de) * 2010-04-13 2014-10-22 F. Hoffmann-La Roche AG Einzelnucleotidpolimorphismus zur vorhersage des ergebnisses einer behandlung bei hcv
US9175332B2 (en) * 2010-07-29 2015-11-03 Roche Molecular Systems, Inc. Generic PCR
US20120077738A1 (en) * 2010-09-24 2012-03-29 Wisconsin Alumni Research Foundation Compositions and methods for predicting hcv susceptibility to antiviral agents
KR101247769B1 (ko) 2011-02-18 2013-03-25 한림대학교 산학협력단 인터페론 알파 저항성 ｃ형 간염 바이러스
AU2013205064B2 (en) * 2012-06-04 2015-07-30 Gen-Probe Incorporated Compositions and Methods for Amplifying and Characterizing HCV Nucleic Acid
CN107699636B (zh) * 2017-11-10 2019-03-15 黑龙江金域医学检验所有限公司 用于检测HCV 2a亚型NS5A耐药突变基因的扩增引物、应用及检测方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6433159B1 (en) * 1992-09-10 2002-08-13 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus associated diseases
ES2214551T3 (es) 1995-11-02 2004-09-16 Schering Corporation Terapia de infusion continua de citocinas a baja dosis.
AUPN976596A0 (en) 1996-05-09 1996-05-30 Pharma Pacific Pty Ltd Stimulation of host defence mechanisms
JP2001514508A (ja) 1997-03-05 2001-09-11 ユニバーシティー オブ ワシントン Ｃ型肝炎ウイルスの複製を選択的に抑制する薬剤を同定するための新規なスクリーニング法
US20030028011A1 (en) 1997-07-30 2003-02-06 Parkin Neil T. Compositions and methods for determining susceptibility of hepatitis C virus to anti-viral drugs
WO2000066141A2 (en) 1999-05-04 2000-11-09 Schering Corporation Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
CN100400101C (zh) * 2000-08-17 2008-07-09 特里帕普股份公司 包含病毒唑的疫苗及其使用方法
CN1093172C (zh) * 2001-03-19 2002-10-23 杨凌岱鹰生物工程股份有限公司 丙型肝炎全病毒及其体外细胞培养方法
AU2003261434A1 (en) 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of hcv replication
KR100520529B1 (ko) * 2003-09-16 2005-10-11 현대자동차주식회사 차량용 6속 자동 변속기의 유압 제어시스템

Also Published As

Publication number Publication date
US20090148831A1 (en) 2009-06-11
CN100422346C (zh) 2008-10-01
JP2005312454A (ja) 2005-11-10
DE602005002673T2 (de) 2008-07-24
US20050260567A1 (en) 2005-11-24
US7504217B2 (en) 2009-03-17
CN1693482A (zh) 2005-11-09
CA2503336A1 (en) 2005-10-29
EP1591539B1 (de) 2007-10-03
JP4097662B2 (ja) 2008-06-11
DE602005002673D1 (de) 2007-11-15
EP1591539A1 (de) 2005-11-02
ES2294589T3 (es) 2008-04-01

Similar Documents

Publication Publication Date Title
DE602005009702D1 (de) Esr1 und gebärmutterhalskrebs
DE60322880D1 (de) Einfache katalytische dna-biosensoren für ionen auf grundlage von farbveränderungen
WO2006044017A3 (en) Systems and methods for identifying diagnostic indicators
ATE444377T1 (de) Nukleinsäurecharakterisierung
DE60322339D1 (de) Bindungsproteine als biosensoren
IL177495A0 (en) Methods of isolating and identifying cells using signaling probes
DK1842920T3 (da) Celler der co-udtrykker K-vitaminreduktase og K-vitaminafhængigt protein, samt anvendelse deraf til at forbedre produktiviteten af det K-vitaminafhængige protein
WO2007034221A3 (en) Non small cell lung cancer therapy prognosis and target
DE602005002673D1 (de) Nukleotidsequenzvariation im Gen NS5A als Marker
ATE426043T1 (de) Verfahren zur identifizierung des brustkrebsrisikos
EP1639127A4 (de) Genetische typisierung auf dna-chip-basis
Laidlaw et al. Interferon lambda: opportunities, risks, and uncertainties in the fight against HCV
ATE480642T1 (de) Verfahren zur bestimmung von genotoxizität
DE602004023766D1 (de) Dot1-histon-methyltransferasen als ziel zur identifizierung von therapeutika gegen leukämie
DE602004022972D1 (de) Mit cmv-resistenz assoziierter molekularer marker und verwendung davon
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
WO2006022619A3 (en) Methods for identifying risk of type ii diabetes and treatments thereof
WO2008002165A3 (en) A method, assay and kit for prediction and treatment of a human subject infected with a virus
ATE406461T1 (de) Rna-bioassay
MXPA05005120A (es) Secuencias de adn de la region genomica tcd de photorhabdus luminescens.
DK1814907T3 (da) Sæt af dele til designet til implementering af en antitumoral eller antiviral behandling hos et pattedyr
SE9900615L (sv) Metod och kit för tidig förutsägelse av cancer
WO2006012356A3 (en) Methods for determining risk of developing regular smoking behavior
ATE319739T1 (de) Menschliche wingless-änhliche gene
EP1907577A4 (de) Verfahren zum screening auf genspezifische hybridisierungspolymorphismen (gshp) und deren verwendung bei der genetischen kartierung und markerentwicklung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties